{
    "clinical_study": {
        "@rank": "63863", 
        "arm_group": [
            {
                "arm_group_label": "Stereotactic Radiosurgery (SRS)", 
                "arm_group_type": "Other", 
                "description": "Patients with brain metastases receiving single fraction Stereotactic Radiosurgery (SRS)."
            }, 
            {
                "arm_group_label": "Whole Brain Radiation Therapy", 
                "arm_group_type": "Other", 
                "description": "Patients with brain metastases receiving fractionated (spread out over time) Whole Brain Radiation Therapy (WBRT)."
            }, 
            {
                "arm_group_label": "Stereotactic Radiation Therapy", 
                "arm_group_type": "Other", 
                "description": "Patients with brain metastases receiving fractionated (spread out over time) Stereotactic Radiation Therapy (FSRT)."
            }
        ], 
        "brief_summary": {
            "textblock": "This study aims to assess changes in vascular permeability in the brain tumor, and in the\n      surrounding brain, due to radiation therapy, using Magnetic Resonance Imaging (MRI)."
        }, 
        "brief_title": "MRI Study of Changes in Blood-Brain/Tumor-Barrier Permeability in Patients With Brain Metastases During and After Radiotherapy", 
        "condition": "Brain Metastases", 
        "condition_browse": {
            "mesh_term": [
                "Neoplasm Metastasis", 
                "Neoplasms, Second Primary", 
                "Brain Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with a histological confirmed malignancy and presence of intraparenchymal\n             brain metastases\n\n          -  Patients are treated by WBRT, SRS, or FSRT\n\n          -  Age greater than or equal to 18 years\n\n          -  A life expectancy of greater than or equal to 8 weeks\n\n          -  Karnofsky performance status (an assessment of general well being and ability to do\n             activities of daily living; scale ranges from 0 to 100 where 100 is perfect health)\n             greater than or equal to 60\n\n          -  Informed consent with signed study-specific informed consent form\n\n        Exclusion Criteria:\n\n          -  Major medical or psychiatric illness, which, in the investigator's opinion, will\n             prevent completion of the protocol\n\n          -  Patients with lepto-meningeal metastases documented by Magnetic Resonance Imagine\n             (MRI), Computed Tomography (CT), or Cerebrospinal Fluid (CSF) evaluation\n\n          -  For patients that will undergo Whole Brain Radiation Therapy (WBRT), previous WBRT is\n             not allowed.  Patients who have had brain metastases managed by Stereotactic\n             Radiosurgery (SRS), Fractionated Stereotactic Radiation Therapy (FSRT), or surgery\n             are eligible\n\n          -  For patients that will undergo Stereotactic Radiosurgery (SRS), previous Whole Brain\n             Radiation Therapy (WBRT) within 5 months prior to study entry is not allowed.  Prior\n             Stereotactic Radiosurgery (SRS), Fractionated Stereotactic Radiation Therapy (FSRT),\n             or surgery is allowed if current treatment will be for a lesion(s) not previously\n             treated.\n\n          -  For patients that will undergo Fractionated Stereotactic Radiation Therapy (FSRT),\n             previous Whole Brain Radiation Therapy (WBRT) within 5 months prior to study entry is\n             not allowed.  Prior Stereotactic Radiosurgery (SRS), Fractionated Stereotactic\n             Radiation Therapy (FSRT), or surgery is allowed if current treatment will be for a\n             lesion(s) not previously treated.\n\n          -  Patients unable to undergo or tolerate MRI scans (presence of cardiac pacemaker,\n             implanted cardiac defibrillator, aneurysm clips, etc).\n\n          -  Patients should have no contraindications to having a contrast enhanced Magnetic\n             Resonance Imaging (MRI) scan.  These contraindications will be assessed at the time\n             of enrollment using the guidelines set up and in clinical use by the University of\n             Michigan.\n\n          -  Women who are pregnant are excluded."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "84", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 13, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02031237", 
            "org_study_id": "UMCC 2005.003", 
            "secondary_id": "HUM00043426"
        }, 
        "intervention": [
            {
                "arm_group_label": "Stereotactic Radiosurgery (SRS)", 
                "intervention_name": "Single Fraction Stereotactic Radiosurgery (SRS)", 
                "intervention_type": "Radiation"
            }, 
            {
                "arm_group_label": "Whole Brain Radiation Therapy", 
                "intervention_name": "Fractionated Whole Brain Radiation Therapy (WBRT)", 
                "intervention_type": "Radiation"
            }, 
            {
                "arm_group_label": "Stereotactic Radiation Therapy", 
                "intervention_name": "Fractionated Stereotactic Radiation Therapy (FSRT)", 
                "intervention_type": "Radiation"
            }, 
            {
                "arm_group_label": [
                    "Stereotactic Radiosurgery (SRS)", 
                    "Whole Brain Radiation Therapy", 
                    "Stereotactic Radiation Therapy"
                ], 
                "intervention_name": "Magnetic Resonance Imaging (MRI) Assessments", 
                "intervention_type": "Device"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "January 7, 2014", 
        "location": {
            "contact": {
                "email": "yuecao@umich.edu", 
                "last_name": "Yue Cao, Ph.D.", 
                "phone": "734-936-8695"
            }, 
            "facility": {
                "address": {
                    "city": "Ann Arbor", 
                    "country": "United States", 
                    "state": "Michigan", 
                    "zip": "48109"
                }, 
                "name": "University of Michigan Hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "MRI Study of Changes in Blood-Brain/Tumor-Barrier Permeability in Patients With Brain Metastases During and After Radiotherapy", 
        "overall_contact": {
            "email": "yuecao@umich.edu", 
            "last_name": "Yue Cao, Ph.D.", 
            "phone": "734-936-8695"
        }, 
        "overall_official": {
            "affiliation": "University of Michigan Cancer Center", 
            "last_name": "Yue Cao, Ph.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "An in-house program, based on a general kinetic model, along with an MRI contrast agent, Gadopentetic Acid (Gd-DTPA), will be used to estimate vascular permeability, per minute, during and after fractionated (total dose spread out over time) Whole Brain Radiation Therapy (WBRT) or single fraction (single-dose) Stereotactic Radiosurgery (SRS).", 
                "measure": "Change in Blood Brain Barrier (BBB)/Blood Tumor Barrier (BTB) permeability (per minute) in patients with brain metastases undergoing radiation therapy.", 
                "safety_issue": "No", 
                "time_frame": "Week -2 to -1, End of Treatment (WBRT), 1-2 Weeks Post Treatment (SRS), 1 Month Post Treatment"
            }, 
            {
                "description": "An in-house program, based on a general kinetic model, along with an MRI contrast agent, Gadopentetic Acid (Gd-DTPA), will be used to estimate vascular permeability (per minute).", 
                "measure": "Change in magnitude and regional variability of Blood Tumor Barrier (BTB)/Blood Brain Barrier (BBB) permeability (per minute) in tumor, tumor margin, normal brain and brain metastases", 
                "safety_issue": "No", 
                "time_frame": "Week -2 to -1, End of Treatment (WBRT), 1-2 Weeks Post Treatment (SRS), 1 Month Post Treatment"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02031237"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Michigan Cancer Center", 
            "investigator_full_name": "Yue Cao", 
            "investigator_title": "Professor of Radiation Oncology, Professor of Radiology, Medical School and Professor of Biomedical Engineering, College of Engineering", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Effect of radiation dose on vascular permeability (per minute) of the Blood Tumor Barrier (BTB)/Blood Brain Barrier (BBB)", 
                "safety_issue": "No", 
                "time_frame": "Week -2 to -1, End of Treatment (WBRT), 1-2 Weeks Post Treatment (SRS), 1 Month Post Treatment"
            }, 
            {
                "measure": "Investigate whether changes in Magnetic Resonance Imaging (MRI) parameters can be used as a marker for early prediction of treatment response in brain metastases.", 
                "safety_issue": "No", 
                "time_frame": "Data is expected to be evaluated beginning 6 months post radiation treatment of the last patient on study"
            }
        ], 
        "source": "University of Michigan Cancer Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Michigan Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2005", 
        "study_design": "Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}